Impact of Hydrocodone Rescheduling on Dental Prescribing of Opioids.

IF 2.2 Q2 DENTISTRY, ORAL SURGERY & MEDICINE
JDR Clinical & Translational Research Pub Date : 2023-10-01 Epub Date: 2022-06-16 DOI:10.1177/23800844221102830
C H Yan, C C Hubbard, T A Lee, L K Sharp, C T Evans, G S Calip, S A Rowan, J C McGregor, W F Gellad, K J Suda
{"title":"Impact of Hydrocodone Rescheduling on Dental Prescribing of Opioids.","authors":"C H Yan,&nbsp;C C Hubbard,&nbsp;T A Lee,&nbsp;L K Sharp,&nbsp;C T Evans,&nbsp;G S Calip,&nbsp;S A Rowan,&nbsp;J C McGregor,&nbsp;W F Gellad,&nbsp;K J Suda","doi":"10.1177/23800844221102830","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>In the United States, dentists frequently prescribe hydrocodone. In October 2014, the US Drug Enforcement Administration rescheduled hydrocodone from controlled substance schedule III to II, introducing more restricted prescribing and dispensing regulations, which may have changed dental prescribing of opioids.</p><p><strong>Objective: </strong>The study aim was to evaluate the impact of the hydrocodone rescheduling on dental prescribing of opioids in the United States.</p><p><strong>Methods: </strong>This was a cross-sectional study of opioids prescribed by dentists between October 2012 and October 2016, using the IQVIA Longitudinal Prescription Dataset. Monthly dentist-based opioid prescribing rate (opioid prescription [Rx]/1,000 dentists) and monthly average opioid dosages per prescription (mean morphine milligram equivalent per day [MME/d]) were measured in the 24 mo before and after hydrocodone rescheduling in October 2014 (index or interruption). An interrupted time-series analysis was conducted using segmented ordinary least square regression models, with Newey-West standard errors to handle autocorrelation.</p><p><strong>Results: </strong>Dentists prescribed 50,412,942 opioid prescriptions across the 49 mo. Hydrocodone was the most commonly prescribed opioid pre- and postindex (74.9% and 63.8%, respectively), followed by codeine (13.8% and 21.6%), oxycodone (8.1% and 9.5%), and tramadol (2.9% and 4.8%). At index, hydrocodone prescribing immediately decreased by -834.8 Rx/1,000 dentists (95% confidence interval [CI], -1,040.2 to -629.4), with increased prescribing of codeine (421.9; 95% CI, 369.7-474.0), oxycodone (85.3; 95% CI, 45.4-125.2), and tramadol (111.8; 95% CI, 101.4-122.3). The mean MME increased at index for all opioids except for hydrocodone, and dosages subsequently decreased during the postindex period.</p><p><strong>Conclusion: </strong>Following the rescheduling, dentist prescribing of hydrocodone declined while prescribing of nonhydrocodone opioids increased. Understanding the impact of this regulation informs strategies to ensure appropriate prescribing of opioids for dental pain.</p><p><strong>Knowledge transfer statement: </strong>The study findings can be used by policy makers to make informed decisions in developing future risk mitigation strategies aimed to regulate opioid prescribing behaviors. Furthermore, dentist-specific resources and guidelines are needed subsequent to these policies in order to meet the dental population needs.</p>","PeriodicalId":14783,"journal":{"name":"JDR Clinical & Translational Research","volume":"8 4","pages":"402-412"},"PeriodicalIF":2.2000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JDR Clinical & Translational Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/23800844221102830","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}
引用次数: 1

Abstract

Introduction: In the United States, dentists frequently prescribe hydrocodone. In October 2014, the US Drug Enforcement Administration rescheduled hydrocodone from controlled substance schedule III to II, introducing more restricted prescribing and dispensing regulations, which may have changed dental prescribing of opioids.

Objective: The study aim was to evaluate the impact of the hydrocodone rescheduling on dental prescribing of opioids in the United States.

Methods: This was a cross-sectional study of opioids prescribed by dentists between October 2012 and October 2016, using the IQVIA Longitudinal Prescription Dataset. Monthly dentist-based opioid prescribing rate (opioid prescription [Rx]/1,000 dentists) and monthly average opioid dosages per prescription (mean morphine milligram equivalent per day [MME/d]) were measured in the 24 mo before and after hydrocodone rescheduling in October 2014 (index or interruption). An interrupted time-series analysis was conducted using segmented ordinary least square regression models, with Newey-West standard errors to handle autocorrelation.

Results: Dentists prescribed 50,412,942 opioid prescriptions across the 49 mo. Hydrocodone was the most commonly prescribed opioid pre- and postindex (74.9% and 63.8%, respectively), followed by codeine (13.8% and 21.6%), oxycodone (8.1% and 9.5%), and tramadol (2.9% and 4.8%). At index, hydrocodone prescribing immediately decreased by -834.8 Rx/1,000 dentists (95% confidence interval [CI], -1,040.2 to -629.4), with increased prescribing of codeine (421.9; 95% CI, 369.7-474.0), oxycodone (85.3; 95% CI, 45.4-125.2), and tramadol (111.8; 95% CI, 101.4-122.3). The mean MME increased at index for all opioids except for hydrocodone, and dosages subsequently decreased during the postindex period.

Conclusion: Following the rescheduling, dentist prescribing of hydrocodone declined while prescribing of nonhydrocodone opioids increased. Understanding the impact of this regulation informs strategies to ensure appropriate prescribing of opioids for dental pain.

Knowledge transfer statement: The study findings can be used by policy makers to make informed decisions in developing future risk mitigation strategies aimed to regulate opioid prescribing behaviors. Furthermore, dentist-specific resources and guidelines are needed subsequent to these policies in order to meet the dental population needs.

羟考酮重新安排对阿片类药物牙科处方的影响。
简介:在美国,牙医经常开氢可酮处方。2014年10月,美国缉毒局将氢可酮从管制物质附表III重新安排为附表II,引入了更严格的处方和配药规定,这可能改变了阿片类药物的牙科处方。目的:本研究旨在评估氢可酮重新安排对美国阿片类药物牙科处方的影响。方法:这是一项使用IQVIA纵向处方数据集对2012年10月至2016年10月期间牙医处方的阿片类物质进行的横断面研究。在2014年10月氢可酮重新安排(指数或中断)前后的24个月内,测量了每月基于牙医的阿片类药物处方率(阿片类处方[Rx]/1000名牙医)和每月平均阿片类剂量(每天平均吗啡毫克当量[MME/d])。使用分段的普通最小二乘回归模型进行中断时间序列分析,Newey West标准误差处理自相关。结果:牙医在49个月内开出了50412942张阿片类药物处方。羟考酮是最常见的阿片类处方(分别为74.9%和63.8%),其次是可待因(13.8%和21.6%)、羟考酮(8.1%和9.5%)和曲马多(2.9%和4.8%),氢可酮处方立即减少了834.8 Rx/1000名牙医(95%置信区间[CI],-1040.2至-629.4),同时增加了可待因(421.9;95%置信区间,369.7-474.0)、羟考酮(85.3;95%可信区间,45.4-125.2)和曲马多(111.8;95%置信度,101.4-122.3)的处方。除氢可酮外,所有阿片类药物的平均MME指数均增加,并且剂量随后在索引后期间减少。结论:重新安排后,牙医对氢可酮的处方减少,而非氢可酮类阿片的处方增加。了解该法规的影响为确保适当开具治疗牙痛的阿片类药物处方提供策略依据。知识转移声明:政策制定者可以利用研究结果,在制定未来旨在规范阿片类药物处方行为的风险缓解策略时做出明智的决定。此外,在这些政策之后,还需要针对牙医的资源和指导方针,以满足牙科人群的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JDR Clinical & Translational Research
JDR Clinical & Translational Research DENTISTRY, ORAL SURGERY & MEDICINE-
CiteScore
6.20
自引率
6.70%
发文量
45
期刊介绍: JDR Clinical & Translational Research seeks to publish the highest quality research articles on clinical and translational research including all of the dental specialties and implantology. Examples include behavioral sciences, cariology, oral & pharyngeal cancer, disease diagnostics, evidence based health care delivery, human genetics, health services research, periodontal diseases, oral medicine, radiology, and pathology. The JDR Clinical & Translational Research expands on its research content by including high-impact health care and global oral health policy statements and systematic reviews of clinical concepts affecting clinical practice. Unique to the JDR Clinical & Translational Research are advances in clinical and translational medicine articles created to focus on research with an immediate potential to affect clinical therapy outcomes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信